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Summary The use of intravitreal vascular endothelial growth
factor (VEGF) inhibitor medications has widened consider-
ably to include indications affecting females of reproductive
age. Our patient was inadvertently exposed to bevacizumab
within the first trimester when placental growth and fetal or-
ganogenesis take place and patient suffered pregnancy loss.
There is insufficient information to suggest that such use is
safe, nor is there definitive evidence to suggest that it causes
harm. We advise that ophthalmologists discuss pregnancy
with women of childbearing age undergoing intraocular anti-
VEGF injections and in pregnant woman counselling is need-
ed to explain the potential risks and benefits.
Keywords Intravitreal vascular endothelial growth factor .
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Introduction
Intravitreal antivascular endothelial growth factor injection is
a beneficial treatment for choroidal neovascularization, retinal
vascular disorders, diabetic retinopathy (PDR), retinopathy of
prematurity and other retinal pathologies [1].
Recent studies have found that after intravitreal injection of
anti-angiogenic agents, these substances can enter the system-
ic circulation [2, 3]. In a study conducted on newborn infants,
bevacizumab concentration in the serum increased with time
after injection into the vitreous cavity [3, 4].
Some female patients are affected by CNV during the
child-bearing age and the safety aspects concerning risks for
the embryonic and fetal development using anti-VEGF agents
such as bevacizumab are of great clinical importance.
Here we describe our experience following intravitreal in-
jection of bevacizumab for the treatment of diabetic retinopa-
thy in a patient during the early unrecognised pregnancy and
we provide the first detailed literature review on bevacizumab
use during pregnancy.
Case report
A 29-year-old Iranian woman presented with a deterioration
of vision in the left eye (LE). She has a 10 year history of type
1 diabetes mellitus but she has no history of hypertension or
dyslipidemia. She is well controlled (diabetes (glycosylated
haemoglobin [HbA1c] = 6 %) on regular insulin 15 U three
times daily and NPH insulin 20 U/day. She has no diabetes-
related complications.
previous gynecologic and medical history was otherwise
unremarkable.
The both eyes of patient was treated 2 years ago with focal
photocoagulation for bilateralmacular edema and pan-retinal
photocoagulation for bilateral proliferative diabetic
retinopathy.
The best corrected visual acuity of the patient’s right eye
was 6/10 and the left eye was 1/10.
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The anterior segment examination and intraocular pressure
of each eye were within normal limits. Fundoscopy revealed
the presence of cystoid macular edema in the left eye.
The patient’s left eye was then treated with a 1.25 mg/
0.05 mL intravitreal bevacizumab injection. 18 h after the
bevacizumab injection, she reported the vaginal bleeding
and ultrasound confirmed a 10-week pregnancy of which the
patient was unaware. Patient suffered pregnancy loss.
Discussion
Safety data on the use of anti-VEGF agents in pregnant pa-
tients are still limited and discussed controversially. Several
studies have reported using of intravitreal bevacizumab during
pregnancy without complication [5–9]. In contrast,There are
several reports of loss of pregnancy after intravitreal injection
of bevacizumab [10, 11].
Of these mothers, 9 were treated in trimester 1 and 2 in
trimester 2 and one in trimester 3. 2 of the pregnant patients
took multiple intravitreal bevacizumab during pregnancy.
3 patients of 14 reported patients had complicated pregnan-
cy following intravitreal bevacizumab including early loss of
pregnancy [10, 11].
Currently, there are no reports of fetal abnormalities in
pregnant women taking intravitreal bevacizumab. Analyzing
the specific risk of intravitreal bevacizumab therapy, overall
15 pregnancies have been reported so far and are summarized
in Table 1.
After intravitreal using of all of anti-VEGF agents, drug
concentrations were detected measurable in the systemic cir-
culation and Serum VEGF levels were suppressed significant-
ly [12].
Bakri et al. [3] reported after injection of bevacizumab into
the vitreous cavity of rabbit eye, the drug can pass through the
eye into systemic circulation and suggested that intravitreal
injection of bevacizumab could potentially have a systemic
effect.
Systemic adverse events included elevated blood pressure,
cerebrovascular accidents and death [13, 14].
Although Maternal IgG antibodies are known to cross the
placenta, it is not known if bevacizumab crosses the human
placenta because adequate or well-controlled studies of preg-
nant women have not been conducted.
As early as 24-h post intravenous injection of bevacizumab
drug was taken up by the fetus in a dose-dependent manner
and in early gestation (day 13) bevacizumab was detectable in
the developing embryo and transferring continued until the
end of pregnancy [15].
In pregnant rabbits, a dose approximately 1 to 12
times the recommended human dose of bevacizumab
confirmed teratogenic effect which include an increased
incidence of specific gross and skeletal fetal alterations.
Adverse fetal outcomes were observed at all doses test-
ed. Other adverse effects included decreases in maternal
and fetal body weights and an increased number of fetal
resorptions [16].
Recent studies suggested that even small amounts of
bevacizumab could migrate into the blood circulation and in-
travitreal injection of bevacizumab may be associated with
systemic and ocular side effects.
In conclusion, the current data of registries and case reports
do not support an increased risk or safety for intravitreal
bevacizumab use during pregnancy or conception. Caution
should be taken when anti-VEGF agents are used during preg-
nancy, and the possibility of ocular side-effects and systemic
side-effects should be explained carefully to patients.
Experience on large cohorts is still extremely limited and is
still awaiting further investigation. Injection of bevacizumab
in young women should be performed after determining that
the patient is not pregnant; patients should be advised to use
birth control after the intravitreal injections. In pregnant pa-
tients, the potential risk of anti-VEGF agents should be bal-
anced against the known risks associated with other medical
treatment alternatives and the risk of active disease and
complications.
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